#156502

STAT2-Defective Mutant Daudi (RST2) cell line

Cat. #156502

STAT2-Defective Mutant Daudi (RST2) cell line

Cat. #: 156502

Sub-type: Continuous

Unit size: 1x10^6 cells / vial

Organism: Human

Tissue: Blood

Disease: Cancer

Model: Transgenic

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Lawrence Pfeffer

Institute: The University of Tennessee Health Science Center

Tool Details
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: STAT2-Defective Mutant Daudi (RST2) cell line
  • Cancer: Blood cancer
  • Cancers detailed: Burkitt lymphoma
  • Research fields: Cancer
  • Tool sub type: Continuous
  • Parental cell: Human Daudi Burkitt Lymphoma cell line
  • Organism: Human
  • Tissue: Blood
  • Disease: Cancer
  • Model: Transgenic
  • Description: This cell line can be used to study drug resistance developed after treatment with interferon. Interferon therapy has been proved as a successful treatment for various types of cancer, however it develops resistance in patients. This cell line was not affected by the antiviral, antiproliferative, and gene-inducing actions of IFN.
  • Production details: Isolated from IFN-sensitive Daudi cell line by growth in the continuous presence of IFN
  • Recommended controls: Human Daudi Burkitt Lymphoma parental line

Handling

  • Format: Frozen
  • Growth medium: RPMI1640 and 10% defined calf serum; Subculture 1:4 twice a week, maintain 1 and 10X10^5 cells/mL
  • Unit size: 1x10^6 cells / vial
  • Shipping conditions: Dry ice

References

  • Schmeisser et al. 2013. Autophagy. 9(5):683-96. PMID: 23419269.
  • Du et al. 2009. J Biol Chem. 284(41):27808-15. PMID: 19687011.